FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038491237> ?p ?o ?g. }

• W2038491237 endingPage "55" @default.
• W2038491237 startingPage "50" @default.
• W2038491237 abstract "BackgroundDabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our prospective observational study aimed to assess the adverse effects, tolerability and patient satisfaction of dabigatran therapy in a hospital-practice population.MethodsPatients starting dabigatran, after its release in June 2011, were identified from clinical practice at two Wellington hospitals, New Zealand. Baseline characteristics were recorded from the clinical record and a telephone interview was performed in January 2012. Primary outcomes included adverse events, adherence, and satisfaction with treatment.ResultsData were available for 70 patients: median age 71.9 years (IQR 62.7–79.0), weight 80 kg (IQR 71–95), CHA2DS2-VASc score 3 (IQR 2–4). Seventy-one percent of patients reported adverse events although the majority were minor. Twenty-four percent (16/70) had discontinued treatment with dabigatran; four due to predominantly gastrointestinal side effects, three due to bleeding (one severe), one as a result of adverse media coverage with the remainder comprising planned treatment discontinuation and undetermined. In total, 29% reported bleeding events, predominantly minor bleeding and bruising. There were no cerebrovascular events. Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses. Seventy-seven percent reported treatment satisfaction and 79% of those previously treated with warfarin preferred dabigatran.ConclusionIn this population our study demonstrates a discontinuation rate of 10% due to side effects of dabigatran, similar to the rate reported in RE-LY. The majority of patients are satisfied with their treatment and preferred dabigatran to warfarin, mainly due to the reduced requirement for blood testing. Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our prospective observational study aimed to assess the adverse effects, tolerability and patient satisfaction of dabigatran therapy in a hospital-practice population. Patients starting dabigatran, after its release in June 2011, were identified from clinical practice at two Wellington hospitals, New Zealand. Baseline characteristics were recorded from the clinical record and a telephone interview was performed in January 2012. Primary outcomes included adverse events, adherence, and satisfaction with treatment. Data were available for 70 patients: median age 71.9 years (IQR 62.7–79.0), weight 80 kg (IQR 71–95), CHA2DS2-VASc score 3 (IQR 2–4). Seventy-one percent of patients reported adverse events although the majority were minor. Twenty-four percent (16/70) had discontinued treatment with dabigatran; four due to predominantly gastrointestinal side effects, three due to bleeding (one severe), one as a result of adverse media coverage with the remainder comprising planned treatment discontinuation and undetermined. In total, 29% reported bleeding events, predominantly minor bleeding and bruising. There were no cerebrovascular events. Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses. Seventy-seven percent reported treatment satisfaction and 79% of those previously treated with warfarin preferred dabigatran. In this population our study demonstrates a discontinuation rate of 10% due to side effects of dabigatran, similar to the rate reported in RE-LY. The majority of patients are satisfied with their treatment and preferred dabigatran to warfarin, mainly due to the reduced requirement for blood testing." @default.
• W2038491237 created "2016-06-24" @default.
• W2038491237 creator A5006447119 @default.
• W2038491237 creator A5040015487 @default.
• W2038491237 creator A5048151163 @default.
• W2038491237 creator A5081118195 @default.
• W2038491237 date "2013-01-01" @default.
• W2038491237 modified "2023-10-16" @default.
• W2038491237 title "Dabigatran for Anticoagulation in Atrial Fibrillation – Early Clinical Experience in a Hospital Population and Comparison to Trial Data" @default.
• W2038491237 cites W1509745955 @default.
• W2038491237 cites W1975650244 @default.
• W2038491237 cites W2062946016 @default.
• W2038491237 cites W2066490209 @default.
• W2038491237 cites W2111670557 @default.
• W2038491237 cites W2117807413 @default.
• W2038491237 cites W2120195951 @default.
• W2038491237 cites W2122779695 @default.
• W2038491237 cites W2127985968 @default.
• W2038491237 cites W2136489990 @default.
• W2038491237 cites W2147797899 @default.
• W2038491237 cites W2152584205 @default.
• W2038491237 cites W2162586165 @default.
• W2038491237 cites W2164861810 @default.
• W2038491237 cites W2203036336 @default.
• W2038491237 cites W2313564639 @default.
• W2038491237 doi "https://doi.org/10.1016/j.hlc.2012.09.002" @default.
• W2038491237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23058974" @default.
• W2038491237 hasPublicationYear "2013" @default.
• W2038491237 type Work @default.
• W2038491237 sameAs 2038491237 @default.
• W2038491237 citedByCount "16" @default.
• W2038491237 countsByYear W20384912372013 @default.
• W2038491237 countsByYear W20384912372014 @default.
• W2038491237 countsByYear W20384912372015 @default.
• W2038491237 countsByYear W20384912372016 @default.
• W2038491237 countsByYear W20384912372017 @default.
• W2038491237 countsByYear W20384912372018 @default.
• W2038491237 countsByYear W20384912372019 @default.
• W2038491237 countsByYear W20384912372020 @default.
• W2038491237 countsByYear W20384912372021 @default.
• W2038491237 crossrefType "journal-article" @default.
• W2038491237 hasAuthorship W2038491237A5006447119 @default.
• W2038491237 hasAuthorship W2038491237A5040015487 @default.
• W2038491237 hasAuthorship W2038491237A5048151163 @default.
• W2038491237 hasAuthorship W2038491237A5081118195 @default.
• W2038491237 hasBestOaLocation W20384912371 @default.
• W2038491237 hasConcept C126322002 @default.
• W2038491237 hasConcept C127413603 @default.
• W2038491237 hasConcept C194828623 @default.
• W2038491237 hasConcept C197934379 @default.
• W2038491237 hasConcept C2776301958 @default.
• W2038491237 hasConcept C2776710957 @default.
• W2038491237 hasConcept C2777288759 @default.
• W2038491237 hasConcept C2778375690 @default.
• W2038491237 hasConcept C2778715236 @default.
• W2038491237 hasConcept C2778810321 @default.
• W2038491237 hasConcept C2779161974 @default.
• W2038491237 hasConcept C2780645631 @default.
• W2038491237 hasConcept C2908647359 @default.
• W2038491237 hasConcept C71924100 @default.
• W2038491237 hasConcept C78519656 @default.
• W2038491237 hasConcept C99454951 @default.
• W2038491237 hasConceptScore W2038491237C126322002 @default.
• W2038491237 hasConceptScore W2038491237C127413603 @default.
• W2038491237 hasConceptScore W2038491237C194828623 @default.
• W2038491237 hasConceptScore W2038491237C197934379 @default.
• W2038491237 hasConceptScore W2038491237C2776301958 @default.
• W2038491237 hasConceptScore W2038491237C2776710957 @default.
• W2038491237 hasConceptScore W2038491237C2777288759 @default.
• W2038491237 hasConceptScore W2038491237C2778375690 @default.
• W2038491237 hasConceptScore W2038491237C2778715236 @default.
• W2038491237 hasConceptScore W2038491237C2778810321 @default.
• W2038491237 hasConceptScore W2038491237C2779161974 @default.
• W2038491237 hasConceptScore W2038491237C2780645631 @default.
• W2038491237 hasConceptScore W2038491237C2908647359 @default.
• W2038491237 hasConceptScore W2038491237C71924100 @default.
• W2038491237 hasConceptScore W2038491237C78519656 @default.
• W2038491237 hasConceptScore W2038491237C99454951 @default.
• W2038491237 hasIssue "1" @default.
• W2038491237 hasLocation W20384912371 @default.
• W2038491237 hasLocation W20384912372 @default.
• W2038491237 hasOpenAccess W2038491237 @default.
• W2038491237 hasPrimaryLocation W20384912371 @default.
• W2038491237 hasRelatedWork W1973989324 @default.
• W2038491237 hasRelatedWork W1993190469 @default.
• W2038491237 hasRelatedWork W2007116565 @default.
• W2038491237 hasRelatedWork W2018572947 @default.
• W2038491237 hasRelatedWork W2022043463 @default.
• W2038491237 hasRelatedWork W2080910965 @default.
• W2038491237 hasRelatedWork W2090821460 @default.
• W2038491237 hasRelatedWork W2097201002 @default.
• W2038491237 hasRelatedWork W2121975441 @default.
• W2038491237 hasRelatedWork W2170786340 @default.
• W2038491237 hasVolume "22" @default.
• W2038491237 isParatext "false" @default.
• W2038491237 isRetracted "false" @default.
• W2038491237 magId "2038491237" @default.
• W2038491237 workType "article" @default.